Skip to main content
Recall Canary
Amgen Corlanor and Sensipar Tablets
← Back to all recalls
DRUG RECALLMODERATE

Amgen Corlanor and Sensipar Tablets

Amgen recalls Corlanor and Sensipar tablets over foreign substance contamination.

What to do

Check your medication bottles for the affected NDCs: Corlanor 5 mg (NDC 55513-800-99 for 14-count, NDC 55513-800-60 for 60-count). Do not use the product. Return it to the place of purchase or contact Amgen for a refund or replacement.

Posted
Updated
Recall No.
D-0615-2026
Agency
Firm
Amgen, Inc.
Recall ID
99077
Status
ONGOING

Why it was recalled

Amgen is recalling Corlanor (ivabradine) tablets, 5 mg, packaged in 14-tablet and 60-tablet bottles, due to the presence of a foreign substance. The recall also includes Sensipar (cinacalcet) tablets in 30 mg, 60 mg, and 90 mg strengths, and Corlanor 7.5 mg tablets, all affected by the same issue.

Is mine affected?

Check the NDC or UPC and strength printed on the package. Yours is affected if it matches one below.

ProductRecall #
Corlanor (ivabradine) tablets, 7.5mg, 60-count bottles, Rx Only, Amgen Inc., Thousand Oaks, CA 92130 Made In Italy. NDC 55513-810-60D-0615-2026
Corlanor (ivabradine) tablets, 5 mg, packaged in a) 14 tablets bottles (NDC 55513-800-99), and b) 60 tablet bottles (NDC 55513-800-60), Rx Only, Amgen Inc., Thousand Oaks, CA 92130 Made In Italy.D-0612-2026
Sensipar (cinacalcet) Tablets, 60mg, 30-count bottles, Rx Only, Distributed by: Amge, One Amgen Center Drive, Thousand Oaks ,CA 91320-1799, Made in Japan. NDC 55513-074-30D-0614-2026
Sensipar (cinacalcet) Tablets, 30mg, 30-count bottles, Rx Only, Distributed by: Amge, One Amgen Center Drive, Thousand Oaks ,CA 91320-1799, Made in Japan. NDC 55513-073-30D-0613-2026
Sensipar (cinacalcet) Tablets, 90mg, 30-count bottles, Rx Only, Distributed by: Amge, One Amgen Center Drive, Thousand Oaks, CA 91320-1799, Made in Japan. NDC 55513-075-30D-0616-2026

Where it was sold

Distributed nationwide.

← Back to all recalls

Editorial summary by Recall Canary · last updated 2026-07-28 · primary source: U.S. Food and Drug Administration · severity reflects the agency's published classification